Open main menu

Psychiatrienet β

Venlafaxine-dosulepine

Revision as of 18:34, 5 May 2009 by Alexandra (talk | contribs)
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine
dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin

Switch medication from venlafaxine to dosulepine.[1] [2]

Nietinrijdenbord.png Stop venlafaxine
  • Day 0: gradually reduce dosage of venlafaxine to a maximum of 75 mg/ day.
  • Day 1: reduce a dosage of 75 mg/day to 37,5 mg/day.
Eenrichtingbord.png Start dosulepine
  • Day 1: simultaneously start administration of dosulepine in a low dosage of 50-75 mg/day.
  • Day 8: stop administration of venlafaxine and continue administration of dosulepine.
Infobord.png More information
  • “Start low, go slow” is not required, but caution with this switch is necessary.
  • Venlafaxine is a weak inhibitor of CYP2D6, which metabolizes dosulepine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.